JOP20170071B1 - ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين - Google Patents

ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين

Info

Publication number
JOP20170071B1
JOP20170071B1 JOP/2017/0071A JOP20170071A JOP20170071B1 JO P20170071 B1 JOP20170071 B1 JO P20170071B1 JO P20170071 A JOP20170071 A JO P20170071A JO P20170071 B1 JOP20170071 B1 JO P20170071B1
Authority
JO
Jordan
Prior art keywords
pyrrol
difluorophenyl
fluorophenyl
sulfonyl
methoxy
Prior art date
Application number
JOP/2017/0071A
Other languages
English (en)
Inventor
Aeri Kim
Kwan Hyung Cho
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JOP20170071B1 publication Critical patent/JOP20170071B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-1H-بيرّول-3-يل)-N-ميثيل ميثان أمين. إن ملح إضافة الحمض الموصوف أعلاه من الممكن أن يكون له ليس فقط نشاط ممتاز مثبط لمضخة بروتون، ونشاط مثبط للضرر المَعِدِي، وتأثير معزز للعامل الدفاعي، ولكن أيضاً قدرة فائقة للقضاء على بكتريا الهيليكوباكتر البوابية(H. pylori)لذلك يمكن استخدامه بفاعلية للوقاية وعلاج الإصابة المعدية المعوية الناتجة عن القرحة المعدية المعوية أو الالتهاب المعِدِي أو التهاب المريء الارتجاعي، أو بكتريا H. pylori.
JOP/2017/0071A 2016-03-25 2017-03-22 ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين JOP20170071B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160036081 2016-03-25
KR1020170018336A KR20170113040A (ko) 2016-03-25 2017-02-09 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염

Publications (1)

Publication Number Publication Date
JOP20170071B1 true JOP20170071B1 (ar) 2021-08-17

Family

ID=60141235

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0071A JOP20170071B1 (ar) 2016-03-25 2017-03-22 ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين

Country Status (28)

Country Link
US (1) US10487053B2 (ar)
EP (1) EP3433232B1 (ar)
JP (1) JP6609065B2 (ar)
KR (2) KR20170113040A (ar)
CN (1) CN108602771B (ar)
AR (1) AR107964A1 (ar)
AU (1) AU2017238917B2 (ar)
CA (1) CA3014753C (ar)
CL (1) CL2018002415A1 (ar)
CO (1) CO2018008834A2 (ar)
DO (2) DOP2018000191A (ar)
ES (1) ES2811478T3 (ar)
HR (1) HRP20201571T1 (ar)
HU (1) HUE053741T2 (ar)
JO (1) JOP20170071B1 (ar)
MA (1) MA43832B1 (ar)
MX (1) MX379775B (ar)
MY (1) MY196355A (ar)
NZ (1) NZ745267A (ar)
PE (1) PE20190169A1 (ar)
PH (1) PH12018501845B1 (ar)
PL (1) PL3433232T3 (ar)
PT (1) PT3433232T (ar)
RS (1) RS60857B1 (ar)
SG (1) SG11201806968RA (ar)
SI (1) SI3433232T1 (ar)
TN (1) TN2018000269A1 (ar)
TW (1) TWI607753B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CA3157981C (en) * 2019-12-18 2024-03-26 Daewoong Pharmaceutical Co., Ltd. Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
MX2022016515A (es) * 2020-06-17 2023-01-30 Ildong Pharmaceutical Co Ltd Nuevo inhibidor de la secrecion de acido y uso del mismo.
JP7777136B2 (ja) * 2020-12-18 2025-11-27 デウン ファーマシューティカル カンパニー リミテッド １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な経口投与用製剤
US20240261261A1 (en) * 2021-05-26 2024-08-08 Daewoong Pharmaceutical Co., Ltd. New formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
WO2022250472A1 (ko) * 2021-05-26 2022-12-01 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기
TW202304426A (zh) * 2021-05-26 2023-02-01 南韓商大熊製藥股份有限公司 用於注射之包含１－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺的新調配物
KR20240119083A (ko) * 2021-12-15 2024-08-06 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US20240415808A1 (en) * 2021-12-15 2024-12-19 Daewoong Pharmaceutical Co., Ltd. Dosage Regimen for Fexuprazan Injection Composition
US20250084026A1 (en) * 2021-12-15 2025-03-13 Ildong Pharmaceutical Co., Ltd. Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
CN119365448A (zh) * 2022-05-23 2025-01-24 日东制药株式会社 一种6-甲氧基吡啶-3-基衍生物的制备方法
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
KR102938657B1 (ko) * 2023-02-15 2026-03-12 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036024A1 (ja) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited プロトンポンプ阻害薬
AU2006285641A1 (en) * 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US9388133B2 (en) 2012-11-19 2016-07-12 Jiangsu Hansoh Pharmaceutical Co., Ltd. Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof
CA2902624C (en) * 2013-02-28 2021-05-18 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
HK1254394A1 (zh) 2019-07-19
US20190031609A1 (en) 2019-01-31
TN2018000269A1 (en) 2020-01-16
US10487053B2 (en) 2019-11-26
PH12018501845B1 (en) 2022-02-18
HRP20201571T1 (hr) 2020-12-11
AU2017238917B2 (en) 2019-07-11
JP2019509320A (ja) 2019-04-04
CO2018008834A2 (es) 2018-10-10
CA3014753A1 (en) 2017-09-28
PL3433232T3 (pl) 2020-12-14
BR112018069540A2 (pt) 2019-01-29
DOP2021000001A (es) 2021-03-15
EP3433232B1 (en) 2020-07-15
PT3433232T (pt) 2020-07-21
MY196355A (en) 2023-03-24
TW201737908A (zh) 2017-11-01
AR107964A1 (es) 2018-07-04
KR102417830B1 (ko) 2022-07-06
CN108602771A (zh) 2018-09-28
DOP2018000191A (es) 2018-09-30
MX379775B (es) 2025-03-11
SG11201806968RA (en) 2018-09-27
TWI607753B (zh) 2017-12-11
AU2017238917A1 (en) 2018-08-16
PH12018501845A1 (en) 2019-05-15
EP3433232A4 (en) 2019-07-31
JP6609065B2 (ja) 2019-11-20
EP3433232A1 (en) 2019-01-30
RS60857B1 (sr) 2020-10-30
CL2018002415A1 (es) 2018-12-28
KR20200105771A (ko) 2020-09-09
KR20170113040A (ko) 2017-10-12
PE20190169A1 (es) 2019-02-01
MX2018009220A (es) 2018-09-10
CN108602771B (zh) 2021-07-16
HUE053741T2 (hu) 2021-07-28
NZ745267A (en) 2020-03-27
SI3433232T1 (sl) 2020-10-30
ES2811478T3 (es) 2021-03-12
MA43832B1 (fr) 2020-08-31
CA3014753C (en) 2023-08-29

Similar Documents

Publication Publication Date Title
JOP20170071B1 (ar) ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
PH12017501755A1 (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201790453A3 (ru) Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EA201990159A1 (ru) Биарилметильные гетероциклы
EA201992306A1 (ru) Ингибиторы ip6k
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
PE20190170A1 (es) Nueva forma cristalina de sal de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
EA201890854A1 (ru) Иминосоединения с 2-хлорпиримидин-5-ильным заместителем в качестве средств борьбы с вредителями
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2021001502A (es) Tratamiento de verrugas.
MX381234B (es) Agente preventivo y/o terapéutico de enfermedad inmune.
TH1801004904A (th) เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน
AR108995A1 (es) 4-alcoxi-3-(acil o alquil)oxipicolinamidas e intermediarios para su preparación
MA38479B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
RU2016138700A (ru) Ингибитор внутреннего пути свёртывания крови
PE20180020A1 (es) Compuestos